You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphomas Non-Hodgkin's B-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)

Not yet recruiting
  • Advanced Solid Tumors
  • B-cell Non-Hodgkin Lymphomas
  • (no location specified)
Aug 31, 2023

Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

Active, not recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Ballarat, Victoria, Australia
  • +2 more
Jan 30, 2023

B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

Not yet recruiting
  • B-cell Non-Hodgkin Lymphoma
  • +4 more
  • (no location specified)
Dec 7, 2022

Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma Trial in China (ATG-101)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Jinan, China
  • +3 more
Aug 3, 2022

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Lymphomas Non-Hodgkin's B-Cell, Relapse Trial in Tianjin (CD19 CAR T cells)

Completed
  • Lymphomas Non-Hodgkin's B-Cell
  • Relapse
  • CD19 CAR T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jan 24, 2022

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • +5 more
  • (no location specified)
Dec 2, 2022

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Changzhou, Jiangsu, China
  • +24 more
Jul 23, 2023

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

Non Hodgkin Lymphoma Trial in Cleveland (UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin Lymphoma
  • UF-KURE19 CAR-T cells
  • +2 more
  • Cleveland, Ohio
  • +1 more
Nov 21, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer Trial in United States

Recruiting
  • Non Small Cell Lung Cancer
  • +11 more
  • Denver, Colorado
  • +3 more
Jan 10, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in United States (radiation,

Recruiting
  • Non-Hodgkin Lymphoma
  • +2 more
  • Bridging radiotherapy (BRT)
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 24, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

Recruiting
  • Advanced Lymphoma
  • +13 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +2 more
  • New Haven, Connecticut
    Yale University Cancer Center LAO
Jun 29, 2022

Patients Receiving CAR-20/19-T Cells

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Long-Term Follow-Up of Participants who Received CAR-20/19-T cells
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Sep 19, 2021

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022